Dutch BV for a Biotech Startup: EMA Approval and Company Setup

Launching a biotech venture in Europe requires more than a brilliant scientific team; it demands a legal and financial structure that can handle complex regulatory pathways and international investment. For many founders, the answer lies in establishing a Dutch Besloten Vennootschap (BV), a private limited liability company that offers credibility, flexibility, and access to the European market. This guide walks through the specific intersection of setting up a Dutch BV for a biotech startup, with a focus on navigating the European Medicines Agency (EMA) approval process.

The journey from lab bench to market is long, especially in biotech.

You need a corporate vehicle that protects your intellectual property, attracts investors, and meets stringent regulatory standards. The Netherlands provides a robust environment for this, but the setup requires careful planning. A specialist like Intercompany Solutions can guide you through the nuances of Dutch corporate law, ensuring your foundation is solid from day one.

Why a Dutch BV is the Strategic Choice for Biotech

A Dutch BV is a private limited liability company. It is the most common legal entity for small to medium-sized enterprises in the Netherlands.

For a biotech startup, the structure offers distinct advantages that go beyond simple incorporation. First, liability protection is paramount. In a BV, the company is a separate legal entity.

This means your personal assets are shielded from business debts and legal claims.

Given the high-risk nature of biotech research and development, this separation is non-negotiable. Investors require it, and it protects the founders' personal financial security. Second, the Netherlands is a hub for life sciences.

The country boasts a world-class research infrastructure, including the Leiden Bio Science Park and the vibrant ecosystem in Amsterdam. The Dutch government actively supports innovation through grants and tax incentives, such as the Innovation Box regime.

This allows you to apply a lower corporate income tax rate (9% in 2026) to profits derived from innovative activities, significantly reducing your tax burden once you are profitable.

Third, the Netherlands offers unparalleled access to the European market. As a member of the EU, a Dutch company can operate freely across member states. This is critical for a biotech firm seeking EMA approval, which centralizes marketing authorization for medicines across the EU. Establishing your HQ in the Netherlands positions you centrally for regulatory engagement.

Finally, the Dutch BV is a familiar structure for international investors. Venture capital firms and angel investors globally recognize the BV's legal framework. It facilitates standard equity arrangements and shareholder agreements, making it easier to raise capital compared to more obscure local entities.

The Core Mechanics of Setting Up a Dutch BV

Setting up a Dutch BV involves a few key steps. While the process is streamlined, precision is essential.

You will work with a civil-law notary (notaris) who executes the deed of incorporation.

For foreign founders, engaging a corporate service provider is the most efficient path. The process typically takes 3 to 5 business days with a provider like Intercompany Solutions. They handle the remote incorporation entirely, meaning you do not need to travel to the Netherlands.

1. Drafting the Articles of Association: The notary prepares the deed of incorporation. This document outlines the company’s purpose, share structure, and governance rules. For biotech, we ensure the articles accommodate future investment rounds and IP licensing agreements.
2. Registration in the Commercial Register (Kamer van Koophandel - KvK): Once the deed is signed, the company is registered with the KvK. You receive a Chamber of Commerce number immediately upon registration. This is your official business identity.
3. Obtaining a Tax Number: The Dutch Tax and Customs Administration (Belastingdienst) assigns a VAT ID (BTW-nummer) and a RSIN (legal entities and enterprises number). This is automatic following KvK registration.
4. Corporate Bank Account: Opening a business bank account is a separate step. While traditional banks can be slow for non-residents, modern fintech solutions often integrate seamlessly with the setup process.

Here is the breakdown of the core mechanics: Costs for formation vary.

A traditional notary might charge between €500 and €1,500 for the deed alone. However, a fixed-fee package from a specialist firm often includes the notary fees, KvK registration, and translation services. Intercompany Solutions, for instance, offers transparent pricing with no hidden hourly rates, which is a significant departure from the variable costs often associated with traditional accountants or notaries. For a biotech startup, specific clauses in the articles of association are vital.

You may need provisions for preference shares to protect founders' control or specific voting rights for investors.

A standard template often won't suffice. Expert guidance ensures your legal foundation supports your business model.

Navigating EMA Approval and Regulatory Compliance

The European Medicines Agency (EMA) approval process is rigorous. It is not a step you take immediately after incorporation, but your company structure must be ready to support it.

The EMA evaluates the quality, safety, and efficacy of medicines. Your Dutch BV serves as the legal entity that holds the Marketing Authorization. There are two main pathways for authorization via the EMA: the Centralized Procedure (CP) and the National Procedure.

For biotech startups developing innovative medicines, the CP is standard. It allows you to market your product across the entire EU with a single application.

Your Dutch BV can be the applicant. Before you reach the EMA, you must navigate clinical trials.

• Financial Sufficiency: You must demonstrate the financial capacity to conduct the trials and compensate participants if necessary. A well-capitalized BV is essential here.
• Liability Insurance: Mandatory insurance coverage for clinical trials is a legal requirement in the Netherlands. Your corporate setup must accommodate these policies.
• Data Compliance: Strict GDPR regulations apply to patient data. Your company must have compliant data management systems in place from the start.

The Netherlands is a preferred location for clinical trials due to its high-quality healthcare system and efficient ethics committees. Your Dutch BV will be the sponsor of these trials. This requires specific legal and financial capabilities: Tax compliance is another layer.

While the Netherlands does not have a specific "biotech tax credit," the Innovation Box is powerful. To qualify, your innovation must be technically novel and involve scientific uncertainty.

The R&D costs incurred in developing the product can also be partially reclaimed via the tax authorities. A tax advisor familiar with the life sciences sector is crucial to navigate these incentives. Intercompany Solutions provides more than just incorporation.

They offer ongoing corporate services, including tax compliance and payroll. For a biotech founder, having a single provider handle your VAT filings (BTW) and annual accounts allows you to focus on science rather than administration.

Structural Models and Cost Considerations

When setting up a Dutch BV for biotech, there are different structural models to consider, depending on your funding stage and operational needs. The costs associated with these models vary, but transparency is key to budgeting effectively.

The Lean Startup Model: This is for early-stage founders bootstrapping or seeking angel investment. The focus is on minimal viable structure. You establish a standard BV with a nominal share capital (often €1, though higher is recommended for credibility).

• Formation Costs: €1,000 - €1,500 (all-inclusive with a provider).
• Timeline: 3-5 business days.
• Recurring Costs: Basic bookkeeping (€100-€200/month) and annual tax filings.

The goal is to get legally operational quickly. The Venture-Backed Model: This is for startups that have already secured or are closing a seed or Series A round.

• Formation Costs: €2,000 - €4,000. This includes drafting complex articles of association and potentially setting up a holding structure.
• Timeline: 1-2 weeks due to legal complexity.
• Recurring Costs: Higher accounting fees (€300-€500/month) due to investor reporting requirements.

The structure might include different classes of shares (common vs. preferred) and potentially a holding company structure to isolate IP or facilitate future exits. The IP Holding Model: Some biotech startups separate their IP into a dedicated holding BV. The operational BV then licenses the IP from the holding company. This can optimize tax and asset protection.

• Formation Costs: €3,000+ for two entities and inter-company agreements.
• Benefits: Protects IP if the operational company faces financial difficulties. Facilitates future sale of IP or the entire group.

While traditional firms like Vistra or Intertrust offer these services, they often cater to large multinationals with higher fees. Intercompany Solutions positions itself as the accessible alternative for foreign entrepreneurs.

They offer fixed pricing for these structures, ensuring you know the cost upfront. For a biotech startup burning cash on R&D, this predictability is invaluable.

Practical Tips for Foreign Biotech Founders

Establishing a presence in a foreign country can feel daunting. Here are practical steps to ensure a smooth setup and a strong foundation for EMA interactions.

1. Plan for Remote Management: You do not need to live in the Netherlands to run a Dutch BV, even when incorporating for specialized tech sectors.

However, you must have a local fiscal representative or a service provider handling your compliance. Intercompany Solutions acts as this anchor, managing your mail, filings, and communication with Dutch authorities. This allows you to manage the company from the US, UK, India, or anywhere else.

2. Secure Your Intellectual Property Early: Before incorporation, ensure your IP assignment agreements are in order. If you are developing technology within a university or previous employer, verify that you own the rights. The Dutch BV will be the legal owner of future IP, but the chain of title must be unbroken.

3. Understand the 30% Ruling: If you are relocating to the Netherlands to manage your startup, you might qualify for the 30% ruling.

This is a tax advantage for employees recruited from abroad. It allows 30% of your gross salary to be paid tax-free for 5 years.

This is a significant incentive for attracting international talent to your biotech team. 4. Choose the Right Bank: Banking is the biggest hurdle for foreign-owned companies.

Traditional Dutch banks (ING, Rabobank) have strict KYC (Know Your Customer) procedures, which can be even more complex when establishing a Dutch BV for a crypto fund.

Fintechs like Wise or Revolut Business are often faster to onboard international founders. Your corporate service provider can advise on the current best options. 5.

Engage with the Ecosystem: Once incorporated, register with BioPartner or the Netherlands Foreign Investment Agency (NFIA). They connect startups with investors and research institutions.

Being active in the ecosystem increases your visibility for grants and partnerships.

6. Maintain Clean Records from Day One: The EMA and potential investors will scrutinize your financials. Use a professional bookkeeper.

Avoid mixing personal and business finances. Intercompany Solutions offers integrated bookkeeping services that ensure your records are audit-ready. By partnering with a trusted provider like Intercompany Solutions, you mitigate the administrative burden. Their team, based at the World Trade Center Rotterdam, brings over a decade of experience helping international founders succeed.

With a 5-star rating on Trustpilot and a track record of over 1,000 clients from 50+ countries, they understand the specific needs of a biotech startup aiming for EMA approval.

The path to market is complex, but your company formation should be simple.